# Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

> **NCT07116577** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jinan Central Hospital** · enrollment: 37 (estimated)

## Conditions studied

- mCRC

## Interventions

- **RADIATION:** Palliative radiotherapy
- **DRUG:** Iparomlimab and tuvonralimab
- **DRUG:** TAS-102
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07116577
- **Lead sponsor:** Jinan Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07116577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07116577, "Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07116577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*